# DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06953089/  
OnCo record `nct06953089` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BNT324 and PM8002 in advanced solid tumours, run by DualityBio Inc., now recruiting.

## Summary

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06953089 by DualityBio Inc., with 450 participants planned, started 2025-07-18 and due to reach its primary completion in 2030-06-30. Interventions recorded: DB-1311/BNT324, BNT327 and DB-1305/BNT325.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06953089
- Phase: 2
- Setting: A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors
- Sponsor: DualityBio Inc.
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06953089: https://clinicaltrials.gov/study/NCT06953089

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BNT324](https://onco.cc/drugs/bnt324/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06953089.json